Fludrocortisone

Synonyms: 氟氢可的松; 9α-Fludrocortisone; 9α-Fluorcortisol
Fludrocortisone (9α-Fludrocortisone) 是一种口服有效的盐皮质激素 (mineralocorticoid) 和糖皮质激素受体 (glucocorticoid receptor) 激动剂,可抑制促炎细胞因子的表达,降低 CCL2、IL-6、IL-8 水平,上调盐皮质激素受体 (MR) 的表达,诱导 PI3K/Akt、GSK-3β、CREB、ERK1/2、mTOR 磷酸化,阻断 Tau 过度磷酸化,抑制细胞凋亡 (apoptosis),促进细胞存活与增殖,增强肾脏的钠水转运功能,增加血浆容量与血压,降低血浆钾离子浓度及肾素活性,刺激促红细胞生成素的表达,调控子宫容受性相关基因,还可逆转 PP242 诱导的 MUC1 上调,可用于先天性肾上腺皮质增生症、体位性低血压及肾上腺功能不全的相关研究。
产品编号: MS-X31900 纯度: 98.99% CAS No.: 127-31-1 分子式: C21H29FO5 分子量: 380.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Fludrocortisone (9α-Fludrocortisone) 是一种口服有效的盐皮质激素 (mineralocorticoid) 和糖皮质激素受体 (glucocorticoid receptor) 激动剂,可抑制促炎细胞因子的表达,降低 CCL2、IL-6、IL-8 水平,上调盐皮质激素受体 (MR) 的表达,诱导 PI3K/Akt、GSK-3β、CREB、ERK1/2、mTOR 磷酸化,阻断 Tau 过度磷酸化,抑制细胞凋亡 (apoptosis),促进细胞存活与增殖,增强肾脏的钠水转运功能,增加血浆容量与血压,降低血浆钾离子浓度及肾素活性,刺激促红细胞生成素的表达,调控子宫容受性相关基因,还可逆转 PP242 诱导的 MUC1 上调,可用于先天性肾上腺皮质增生症、体位性低血压及肾上腺功能不全的相关研究。

生物实验数据

生物活性 Fludrocortisone (9α-Fludrocortisone) is an orally active mineralocorticoid and glucocorticoid receptor agonist that inhibits the expression of pro-inflammatory cytokines, reduces CCL2, IL-6, and IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces phosphorylation of PI3K/Akt, GSK-3β, CREB, ERK1/2, and mTOR, blocks Tau hyperphosphorylation, inhibits apoptosis, promotes cell survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, decreases plasma potassium concentration and renin activity, stimulates erythropoietin expression, regulates genes related to uterine receptivity, and reverses PP242-induced MUC1 upregulation, and can be used for research on congenital adrenal hyperplasia, orthostatic hypotension, and adrenal insufficiency.
体外研究
(In Vitro)

Fludrocortisone (0.01-10 μg/μL; 12 h) 在浓度不超过 1 μg/μL 时,对 MIO-M1、ARPE19 和 661W 人视网膜细胞系无细胞毒性,仅在 10 μg/μL 浓度下的 MIO-M1 和 661W 细胞中观察到细胞活力下降。
Fludrocortisone (1 μg/μL; 12 h) 可强效抑制 IL-1β 和 TNF-α 诱导的人 Müller 胶质细胞系 MIO-M1 中 CCL2、IL-6 和 IL-8 的 mRNA 表达。
Fludrocortisone (1 μM; 24 h) 可在不改变糖皮质激素受体 (GR) 表达的情况下,上调 AHPs 中的盐皮质激素受体 (MR) 基因表达。
Fludrocortisone (0.5-2 μM; 24 h) 可在生长因子缺失的 AHP 中促进细胞存活与增殖,并减少细胞凋亡,其中 1 μM 为最适浓度。
Fludrocortisone (1 μM) 可激活 AHPs 中的 cAMP/PKA/CREB 信号通路,这是其发挥促存活和促增殖作用所必需的。
Fludrocortisone (1 μM) 可激活 PI3K/Akt 及 mTOR/p70S6K 信号通路,并使 GSK-3β 失活,这是其在生长因子缺失的 AHP 中发挥保护作用所必需的。
Fludrocortisone (1 μM) 可通过促进存活与增殖、减少细胞凋亡、恢复 Akt/GSK-3β 磷酸化并阻断 Tau 过度磷酸化,保护 AHPs 免受 Aβ1-42 诱导的毒性损伤。
Fludrocortisone (4-6 h) 可刺激显微分离的大鼠肾单位节段、小鼠肾单位节段及肾小管周细胞中的 Epo、HIF2α、HIF1α 和 PHD2 mRNA 表达,与基础状态相比显著升高。
Fludrocortisone (6 h, 72 h) 相对于基础状态可显著上调大鼠肾皮质中 Epo 蛋白的表达,但对大鼠肝脏中的 Epo 蛋白表达无此作用。
Fludrocortisone (4-6 h) 可刺激小鼠 MAL、CCD 和 OMCD 中 Epo 蛋白的产生,且在集合管 A 型闰细胞中存在特异性上调,其作用在 72 h 时降至基础水平。

Cell Viability Assay

Cell Line: human MIO-M1 Müller glial cells, ARPE19 retinal pigment epithelial cells, 661W cone photoreceptor-like cells
Concentration: 0.01-10 μg/μL
Incubation Time: 12 h
Result: Did not significantly alter cell viability in ARPE19 cells at all tested concentrations. Showed unchanged viability in MIO-M1 and 661W cells at 0.01, 0.1, and 1 μg/μL; caused a slight but statistically significant reduction in viability only at the highest concentration of 10 μg/μL in MIO-M1 and 661W cells.

Real Time qPCR

Cell Line: human MIO-M1 Müller glial cells
Concentration: 1 μg/μL
Incubation Time: 12 h (co-incubated with IL-1β stimulation)
Result: Completely abrogated IL-1β-induced significant increases in CCL2, IL-6, and IL-8 mRNA expression, suppressing expression to near baseline levels.

Real Time qPCR

Cell Line: human MIO-M1 Müller glial cells
Concentration: 1 μg/μL
Incubation Time: 12 h (co-incubated with TNF-α stimulation)
Result: Sharply reduced TNF-α-induced significant increases in CCL2, IL-6, and IL-8 mRNA expression, suppressing expression to near baseline levels.

Real Time qPCR

Cell Line: Human MIO-M1 Müller glial cells
Concentration: 1 μg/μL
Incubation Time: 12 h (co-incubated with IL-1β stimulation)
Result: Had its suppressive effect on IL-1β-induced CCL2, IL-6, and IL-8 expression completely abrogated by co-incubation with glucocorticoid receptor antagonist RU486.

Real Time qPCR

Cell Line: Adult rat hippocampal progenitor cells (AHPs)
Concentration: 1 μM
Incubation Time: 24 h
Result: Strongly increased mineralocorticoid receptor (MR) gene expression; showed no significant change in glucocorticoid receptor (GR) gene expression.

Cell Viability Assay

Cell Line: Adult rat hippocampal progenitor cells (AHPs)
Concentration: 0.01, 0.1, 0.5, 1, 2 μM
Incubation Time: 24 h
Result: Progressively increased cell survival and proliferation at 0.5, 1, and 2 μM; strongly reduced serum starvation-induced apoptosis (via decreased caspase-3 activity) at 0.5, 1, and 2 μM; identified 1 μM as the optimal concentration for subsequent experiments.

Western Blot Analysis

Cell Line: adult rat hippocampal progenitor cells (AHPs)
Concentration: 1 μM (cAMP/CREB phosphorylation assays); 1 μM (functional validation with KT5720)
Incubation Time: 5, 15, 30, 60, 90 min (cAMP/CREB phosphorylation assays); 24 h (functional validation with KT5720)
Result: Increased intracellular cAMP levels, with a peak at 15 min and sustained elevation through 90 min; promoted CREB phosphorylation (Ser133), peaking at 15-30 min and returning to near basal levels by 90 min; had induced survival and proliferation reduced by co-treatment with PKA inhibitor KT5720.

Western Blot Analysis

Cell Line: adult rat hippocampal progenitor cells (AHPs)
Concentration: 1 μM (phosphorylation assays); 1 μM (functional validation with wortmannin/rapamycin)
Incubation Time: 5, 15, 30, 60, 90 min (phosphorylation assays); 24 h (functional validation with wortmannin/rapamycin)
Result: Induced time-dependent phosphorylation of Akt (peaking at 30 min, sustained through 90 min), GSK-3β (sustained elevation from 5 to 90 min), and p70S6K (progressive elevation through 90 min); had induced survival, proliferation, and antiapoptotic effects reduced by co-treatment with Wortmannin or Rapamycin.
体内研究
(In Vivo)

Fludrocortisone (1 μg/μL; intravitreal injection (3 μL); single dose) 在小鼠光氧化视网膜变性模型中发挥神经保护作用,可维持视网膜结构与功能、减少光感受器细胞凋亡并抑制巨噬细胞浸润。
Fludrocortisone (1.5 mg/kg; i.p.; twice on Days 4 and 5 of pregnancy) 可通过上调 LIF、HB-EGF、Msx.1 和 miRNA Let-7a 的表达并激活 ERK1/2-mTOR 通路,在不改变 MUC1 或 miRNA 223-3p 表达的情况下,调节妊娠 BALB/c 小鼠的子宫容受性。
Fludrocortisone (1.5 mg/kg; i.p.; twice on Days 4 and 5 of pregnancy) 与 PP242 (30 mg/kg) 联合给药可逆转 PP242 诱导的MUC1上调,并恢复妊娠BALB/c小鼠中关键子宫容受性基因 (LIF、HB-EGF、Msx.1、miRNA Let-7a) 的上调。
Fludrocortisone (2.5 mg/100 g BW/day; i.p.; daily) 可在雄性 Sprague Dawley 大鼠中刺激肾脏 Epo mRNA 表达 (4 小时达峰值) 和 Epo 蛋白表达 (6 小时和 72 小时),给药后 6 小时血浆 Epo 浓度出现具有统计学意义的升高。

Animal Model: C57BL/6J (60 post-natal days old)
Dosage: 1 μg/μL
Administration: intravitreal injection; single dose
Result: Preserved outer nuclear layer thickness at locations 1-2 mm and 2-3 mm superior to the optic nerve compared to controls; Achieved significantly higher a-wave and b-wave ERG responses; Reduced the number of TUNEL+ apoptotic photoreceptors significantly compared to vehicle-treated mice; Decreased the number of subretinal IBA1+ macrophages significantly compared to vehicle-treated mice.
Animal Model: BALB/c (8-week-old virgin female; pregnancy model, estrous induced, mated with fertile males, vaginal plug confirmed)
Dosage: 1.5 mg/kg
Administration: i.p.; twice on Days 4 and 5 of pregnancy at 8:00 a.m.
Result: Did not significantly alter mRNA expression of mucin-1 (MUC1) or miRNA 223-3p; significantly upregulated mRNA expression of leukemia inhibitory factor (LIF), heparin-binding epidermal growth factor (HB-EGF, Msx.1, and miRNA Let-7a; significantly increased phosphorylated ERK1/2 (p-ERK1/2) and phosphorylated mammalian target of rapamycin (p-mTOR) levels; did not change phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 (p-4E-BP1) levels significantly; induced round epithelial cell nuclei, cuboidal endometrial epithelium, no detectable glycoprotein layer on the epithelial surface, a thin continuous basement membrane beneath epithelial cells, and proliferating fibroblast-like stromal cells.
Animal Model: BALB/c (8-week-old virgin female; pregnancy model, estrous induced, mated with fertile males, vaginal plug confirmed)
Dosage: 1.5 mg/kg (fludrocortisone); 30 mg/kg (PP242)
Administration: i.p.; twice on Days 4 and 5 of pregnancy at 8:00 a.m. (fludrocortisone); co-administered with PP242
Result: Significantly upregulated mRNA expression of LIF, HB-EGF, Msx.1, and miRNA Let-7a compared to PP242-only group; significantly downregulated mRNA expression of MUC1 compared to PP242-only group; did not change miRNA 223-3p expression significantly compared to PP242-only group.
Animal Model: Sprague Dawley (male)
Dosage: 2.5 mg/100 g BW/day
Administration: i.p.; daily
Result: Increased Epo, HIF2α, and HIF1α mRNA expression in renal cortex at 4 hours post-injection; the stimulating effect disappeared by 72 hours. Increased Epo protein expression in renal cortex at 6 and 72 hours. Increased plasma Epo concentration at 6 hours (statistically significant elevation vs. vehicle), but not at 72 hours. Did not alter Epo mRNA or protein expression in the liver.
性状 固体
颜色 White to off-white

化学信息

分子量 380.45
分子式 C21H29FO5
CAS No. 127-31-1
别名 氟氢可的松; 9α-Fludrocortisone; 9α-Fluorcortisol

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 5.56 mg/mL (14.61 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.56 mg/mL (14.61 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (262.85 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.6285 mL13.1423 mL26.2847 mL65.7117 mL
5 mM0.5257 mL2.6285 mL5.2569 mL13.1423 mL
10 mM0.2628 mL1.3142 mL2.6285 mL6.5712 mL
15 mM0.1752 mL0.8762 mL1.7523 mL4.3808 mL
20 mM0.1314 mL0.6571 mL1.3142 mL3.2856 mL
25 mM0.1051 mL0.5257 mL1.0514 mL2.6285 mL
30 mM0.0876 mL0.4381 mL0.8762 mL2.1904 mL
40 mM0.0657 mL0.3286 mL0.6571 mL1.6428 mL
50 mM0.0526 mL0.2628 mL0.5257 mL1.3142 mL
60 mM0.0438 mL0.2190 mL0.4381 mL1.0952 mL
80 mM0.0329 mL0.1643 mL0.3286 mL0.8214 mL
100 mM0.0263 mL0.1314 mL0.2628 mL0.6571 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础